Medicine and Dentistry
Patient
100%
Prostate Cancer
97%
Inpatient
96%
Therapeutic Procedure
55%
Morbidity
47%
Castration Resistant Prostate Cancer
47%
Quality of Life
37%
Urinary System
32%
Radiation Therapy
25%
Surveillance
25%
Physician
25%
Gemcitabine
23%
Cisplatin
23%
Prostatectomy
23%
Progressive Disease
23%
Placebo
23%
Prostate Specific Membrane Antigen
23%
Lutetium 177
23%
Bone Scintigraphy
23%
PET-CT
23%
Carboplatin
23%
Pelvis
23%
Maintenance Therapy
23%
Docetaxel
23%
Radiation
23%
Treatment Response
23%
Transitional Cell Carcinoma
23%
Bone Metastasis
23%
Assessment
23%
Testis Cancer
23%
Amaurosis
23%
Fluorine-18
23%
Arm
21%
Incidence
18%
Patient-Reported Outcome
18%
Adverse Event
17%
Relapse
15%
Progression Free Survival
13%
Famotidine
10%
Follow up
8%
Combination Therapy
8%
Overall Survival
8%
Chemotherapy
6%
Prevalence
6%
Cancer Therapy
6%
Hormone Therapy
5%
Pharmacology, Toxicology and Pharmaceutical Science
Gemcitabine
47%
Cisplatin
47%
Castration Resistant Prostate Cancer
47%
Chemotherapy
27%
Prostate Cancer
26%
Morbidity
23%
Lutetium 177
23%
Carboplatin
23%
Docetaxel
23%
Transitional Cell Carcinoma
23%
Muscle Invasive Bladder Cancer
23%
Phase II Trials
23%
Blindness
23%
Adverse Event
17%
Incidence
17%
Progression Free Survival
13%
Overall Survival
8%
Malignant Neoplasm
7%
Nursing and Health Professions
Patient
33%
Gemcitabine
23%
Morbidity
23%
Prostate Cancer
23%
Quality of Life
23%
Cisplatin
23%
Prostatectomy
23%
Radiotherapy
23%
Dose
23%
